This study - designed, executed and analyzed
by research professionals from the drug development and
commercialization industry - sheds light on prescribers' views of
biosimilars. It is based on interviews with 264 physicians in the United
States and Western Europe. Respondents provided their beliefs,
attitudes, intentions, and expectations on a number of biosimilar
related topics including:
Sponsors and service providers can rely on this report to provide an important perspective on their development and commercialization strategies for Biosimilar products.
Other Measurements Reported
Published: June 2012 Price: US $ 750
- Regulatory issues
- Safety and efficacy
- Prescribing / Pricing
- Development / Testing rigor
- Differences between "generic" and "novel" manufacturers
Sponsors and service providers can rely on this report to provide an important perspective on their development and commercialization strategies for Biosimilar products.
Other Measurements Reported
- Adoption of prescribing
- Anticipated pricing (discount level)
- Generic vs. innovator manufacturing safety and efficacy
Published: June 2012 Price: US $ 750
Table Of contents
This report is divided into four major sections
1. Regulatory Awareness
2. Safety and Efficacy
3. Perceptions of Generic and Innovator Companies
4. Prescribing Behavior
As always, an appendix of Charts and Graphs is also included within this report with responses to all questions asked in this study
This report is divided into four major sections
1. Regulatory Awareness
2. Safety and Efficacy
3. Perceptions of Generic and Innovator Companies
4. Prescribing Behavior
As always, an appendix of Charts and Graphs is also included within this report with responses to all questions asked in this study
No comments:
Post a Comment